Motivation: Insulin resistance in skeletal muscle plays a central role in the development of type 2 diabetes (T2D). T2D genome-wide association studies (GWAS) have nominated > 600 signals potentially linked to cell type-specific regulatory processes, with most lying in the non-coding region. Studying the genetic regulation of local chromatin patterns in muscle fibers can provide mechanistic insights into T2D GWAS hits. Here, we employ population-scale single-nucleus ATAC-sequencing (snATAC) to better understand T2D mechanisms.

Methods: Leveraging snATAC profiles from 281 individuals, we used statistical models to infer nucleosome positioning and nucleosome-free regions (NFR). We then combined genetic variation with chromatin accessibility patterns to identify cis-quantitative trait loci (QTL) for both NFR (nfrQTL) and nucleosome positioning (nucQTL) globally and at T2D-related trait GWAS signals.

Results: We identified 14,417 nfrQTLs and 19,265 nucQTLs (5% FDR) in type 1 muscle fibers. NfrQTLs were significantly enriched to overlap T2D and fasting insulin signals (P < 0.005). Colocalization analyses revealed that 5,890 pairs of nfr- and nucQTLs contained shared causal variants. Furthermore, mediation analyses revealed that at 765 pairs of colocalized nfr&nucQTLs, genetic variant(s) regulated the nucleosome positioning through NFRs and 65 pairs with the reverse direction (5% FDR). Notably, 25 nfrQTLs colocalized with T2D GWAS signals. Interestingly, signals at FARSA and PLEKHA1 colocalized with both nfr- and nucQTLs, and the nfrQTLs were causal on the nucQTLs. These findings imply that genetic variants in these GWAS signals regulate the NFR's position, which subsequently influences nucleosome positioning.

Conclusion: These results provide single-nucleus resolution mechanistic hypotheses for local chromatin dynamics in skeletal muscle, providing significant insights into T2D therapeutic strategies involving NFRs.

Disclosure

X. Wang: None. C. Robertson: None. A. Varshney: None. N. Manickam: Employee; 10x Genomics. P. Orchard: None. M. Laakso: None. J. Tuomilehto: Stock/Shareholder; Orion Pharma, Aktivolabs, Digostics. T.A. Lakka: None. K.L. Mohlke: None. M. Boehnke: None. L. Scott: None. H.A. Koistinen: Other Relationship; AstraZeneca, Novo Nordisk. F.S. Collins: None. S. Parker: Research Support; Pfizer Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.